300583 Shandong Sito Bio-technology
- 27.58
- +2.78+11.21%
Shandong Sito Bio-technology News
Saito Biotech: Report for the third quarter of 2024
Express News | Shandong Sito Bio-technology: The company's operation is normal.
Saito Biotech: 2024 Semi-Annual Report
Saito Biotech: 2024 Semi-Annual Report Summary
Shandong Sito Bio-Technology (300583.SZ): The net income in the first half of the year was 13.2114 million yuan, a year-on-year decrease of 77.97%.
On August 26th, Shandong Sito Bio-Technology (300583.SZ) released its semi-annual report for 2024. During the reporting period, the total operating revenue was 0.567 billion yuan, a decrease of 14.62% year-on-year. The net income attributable to shareholders of the listed company was 13.2114 million yuan, a decrease of 77.97% year-on-year. After deducting non-recurring gains and losses, the net income attributable to shareholders of the listed company was 5.05 million yuan, a decrease of 86.40% year-on-year. The basic earnings per share were 0.07 yuan.
Shandong Sito Bio-Technology (300583.SZ): Budesonide received the approval notice for the active pharmaceutical ingredient application for marketing.
On August 19th, Gelon Hui reported that Shandong Sito Bio-technology (300583.SZ), a subsidiary of the company, received the approval notice of budesonide active pharmaceutical ingredient for marketing application issued by the National Medical Products Administration. Budesonide API can be used to produce various dosage forms of drugs such as budesonide inhalation powder, inhalation aerosol, inhalation suspension and nasal spray. Budesonide is a glucocorticoid with highly effective localized anti-inflammatory and anti-allergic effects, which is clinically used to treat asthma, allergic rhinitis and prevent and treat nasal polyps.
Express News | Shandong Sito Bio-Technology: there are no major issues related to the company, controlling shareholders, or actual controllers that should be disclosed but have not been disclosed.
Express News | 25 individual stocks had a trading volume ratio of more than five times in the past five days.
Shandong Sito Bio-technology (300583.SZ) will distribute CNY 4.5 dividends per 10 shares for the year 2023, with the registration date on July 29th.
Shandong Sito Bio-Technology (300583.SZ) announced that the company will implement annual equity distribution for 2023, distributing 1.5 yuan (tax included) for every 10 shares.
Shandong Sito Bio-technology Disposes 90.43% Stake in Losing Italian Unit for 1 Euro
Shandong Sito Bio-Technology (300583.SZ): intends to transfer 90.43% equity and debt exemption of Lisapharma Company.
On June 7th, LearnHu announced that its wholly-owned subsidiary, Yihua Stock Limited (Hong Kong) held 90.43% equity of Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.p.A. (referred to as "Lisapharma Company" or "target company"), and Yihua Stock Limited intends to transfer the equity to Far East Trading Co., Ltd. (referred to as "Far East Trading" or "investor"). The company considers the target company comprehensively.
Express News | Shandong Sito Bio-Technology: plans to transfer 90.43% of overseas company's equity for 1 euro.
Express News | Certo Biotech: The subsidiary obtained marketing approval for fluticasone propionate as a chemical raw material
Saito Biotech (300583.SZ): Jinsaifu Biotech is mainly engaged in standardized cultivation of Chinese herbal medicines such as saffron and carbon-based chaihu, not involving longevity medicine
Gelonghui, May 23 | Saito Biotech (300583.SZ) said on the investor interactive platform that Runxin Thermal Power mainly provides steam heat to the industrial park where the company is located. Rongjun New Materials plans to supply some accessories for the company, and production and operation have not yet started. Jinsaifu Biotech is a company participating in the company. It is mainly engaged in standardized cultivation of Chinese herbal medicines such as saffron and carbon-based chaihu. It does not involve longevity medicine, and the company does not participate in specific operations. All of the company's business layout and expansion revolves around the company's industrial upgrading strategy to achieve the integrated development of “intermediates - high-end respiratory APIs - preparations”.
Saito Biotech (300583.SZ): The company is not involved in cellular immunotherapy technology
Gelonghui, May 10 | Saito Biotech (300583.SZ) is a good vanguard of investors. The company's main products are produced using genetic engineering technology and synthetic biological methods. Compared with traditional chemical production methods, the technology currently used by the company has the advantage of “two high, two low and one stable”. The company is not currently involved in cellular immunotherapy technology. Silver Valley Pharmaceutical, which is in the process of being acquired, is carrying out the opening and promotion of the new drug phenylcycloquine ammonium bromide nasal spray according to the plan.
Saito Biotech (300583.SZ): Using synthetic biological methods to produce the five major parent nuclear products of steroidal raw materials such as androstenedione, androstenedione, 9-hydroxyandrostenedione, and dialcohol
Gelonghui, May 8 | Saito Biotech (300583.SZ) said on the investor interactive platform that the company uses synthetic biological methods to produce five major parent core products with steroidal ingredients such as androstenedione, androstenedione, 9-hydroxyandrostenedione, and dialcohol to develop glucocorticoids, sex hormones, progesterone, and anabolic steroid drugs.
Express News | Saito Biotech: The company uses synthetic biological methods to produce five major parent nuclear products including androstenedione
Shandong Sito Bio-technology Gets European Suitability Certification for Rhinitis Nasal Spray
Express News | Certo Biotech: The subsidiary received the European CEP certificate for fluticasone propionate chemical raw materials
Express News | Saito Biotech: The company relies on synthetic biological methods and product advantages to establish cooperative relationships with many well-known steroidal drug companies
Analysis
Price Target
No Data
No Data